BR112019012251A2 - métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares - Google Patents

métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares Download PDF

Info

Publication number
BR112019012251A2
BR112019012251A2 BR112019012251-6A BR112019012251A BR112019012251A2 BR 112019012251 A2 BR112019012251 A2 BR 112019012251A2 BR 112019012251 A BR112019012251 A BR 112019012251A BR 112019012251 A2 BR112019012251 A2 BR 112019012251A2
Authority
BR
Brazil
Prior art keywords
carrier
fact
vasodilator
drug
dose
Prior art date
Application number
BR112019012251-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Weers Jeffrey
Romero Alain
Smyth Hugh
Curtis Robert
frost Adaani
Xu Zhen
Shreeniwas Revati
Donovan Martin
Original Assignee
Respira Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respira Therapeutics, Inc filed Critical Respira Therapeutics, Inc
Publication of BR112019012251A2 publication Critical patent/BR112019012251A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019012251-6A 2016-12-14 2017-12-14 métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares BR112019012251A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434185P 2016-12-14 2016-12-14
US62/434185 2016-12-14
PCT/US2017/066519 WO2018112258A1 (en) 2016-12-14 2017-12-14 Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Publications (1)

Publication Number Publication Date
BR112019012251A2 true BR112019012251A2 (pt) 2019-11-05

Family

ID=60888760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012251-6A BR112019012251A2 (pt) 2016-12-14 2017-12-14 métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares

Country Status (10)

Country Link
US (5) US10912778B2 (https=)
EP (2) EP4620525A3 (https=)
JP (3) JP2020502121A (https=)
CN (1) CN110381951A (https=)
AU (3) AU2017378409A1 (https=)
BR (1) BR112019012251A2 (https=)
CA (1) CA3046025A1 (https=)
MX (1) MX2019006938A (https=)
RU (1) RU2019121646A (https=)
WO (1) WO2018112258A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
WO2018132371A2 (en) * 2017-01-10 2018-07-19 United Therapeutics Corporation Methods and compositions for treating pulmonary hypertension
KR20210150495A (ko) 2019-04-10 2021-12-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 심혈관 기능장애의 성별-의존적 치료를 위한 방법 및 재료
CA3142758A1 (en) * 2019-06-10 2020-12-17 Respira Therapeutics,Inc. Carrier-based formulations and related methods
CN112569210B (zh) * 2019-09-27 2023-09-15 盈科瑞（天津）创新医药研究有限公司 一种吸入用马昔腾坦溶液及其制备方法
CN112773898A (zh) * 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
BR112022019274A2 (pt) 2020-03-31 2022-11-16 Softhale Nv Entrega de aerossol de pelo menos duas composições líquidas
US11013688B1 (en) * 2020-05-28 2021-05-25 Softhale Nv Methods of treatment of viral diseases
WO2022094100A1 (en) * 2020-10-28 2022-05-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
US20250000873A1 (en) * 2021-09-10 2025-01-02 Justus-Liebig-Universitaet Giessen Inhaled iloprost for rescue treatment and treatment as needed in pulmonary hypertension
WO2024249775A2 (en) * 2023-05-31 2024-12-05 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN116687888A (zh) * 2023-06-02 2023-09-05 苏州易合医药有限公司 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4883810A (en) 1976-08-17 1989-11-28 Burroughs Wellcome Co. Ethers
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DE3417638A1 (de) 1984-05-10 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CA2395558C (en) 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
PT1200090E (pt) 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
CN1374953A (zh) 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
CN1264574C (zh) 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
IL157009A0 (en) 2001-03-28 2004-02-08 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
CA2536293A1 (en) * 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
CA2612917A1 (en) 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
CN101410119B (zh) 2006-02-03 2012-03-07 埃科特莱茵单一股份公司 依前列醇制剂及其制备方法
EP2026816B1 (en) 2006-05-15 2018-10-24 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
CN101903324B (zh) 2007-12-17 2013-07-03 联合治疗公司 一种制备Remodulin中的活性成分曲前列素的改良方法
EP2237788A4 (en) 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF
WO2009117095A1 (en) 2008-03-18 2009-09-24 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
WO2009115235A1 (en) 2008-03-20 2009-09-24 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of pulmonary hypertension
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
WO2011037613A1 (en) 2009-09-23 2011-03-31 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
ES2611187T3 (es) * 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
BR112012028153A2 (pt) 2010-05-03 2018-08-07 Tsh Biopharm Corporation Ltd composição farmacêutica e método para o tratamento de hipertensão
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US8561609B2 (en) 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
WO2014067699A1 (en) 2012-10-31 2014-05-08 Activaero Gmbh Administration of aerosolised iloprost
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
WO2015127258A2 (en) 2014-02-21 2015-08-27 Respira Therapeutics, Inc. Powder inhaler, system and methods
CN107427698A (zh) * 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
MX2019006938A (es) 2016-12-14 2019-09-06 Respira Therapeutics Inc Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.

Also Published As

Publication number Publication date
RU2019121646A3 (https=) 2021-03-17
WO2018112258A1 (en) 2018-06-21
EP4620525A3 (en) 2025-12-03
US20210205318A1 (en) 2021-07-08
JP2025065408A (ja) 2025-04-17
US11491160B2 (en) 2022-11-08
US20250195531A1 (en) 2025-06-19
MX2019006938A (es) 2019-09-06
US20220347183A1 (en) 2022-11-03
AU2025260006A1 (en) 2025-11-20
JP2023036678A (ja) 2023-03-14
US11491161B2 (en) 2022-11-08
CA3046025A1 (en) 2018-06-21
EP4620525A2 (en) 2025-09-24
US12263174B2 (en) 2025-04-01
AU2022256085A1 (en) 2022-11-17
AU2017378409A1 (en) 2019-07-04
EP3554507A1 (en) 2019-10-23
US20200093830A1 (en) 2020-03-26
US10912778B2 (en) 2021-02-09
CN110381951A (zh) 2019-10-25
RU2019121646A (ru) 2021-01-15
JP2020502121A (ja) 2020-01-23
US20220079949A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
US12263174B2 (en) Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US4232002A (en) Procedures and pharmaceutical products for use in the administration of antihistamines
ES2638987T3 (es) Epinefrina inhalable
ES2872350T3 (es) Polvos farmacéuticos de dosis baja para inhalación
KR20010042531A (ko) 랄록시펜의 폐 및 경비 전달
JP2019519489A (ja) 肺高血圧症を治療するための乾燥粉末トレプロスチニル
BRPI0619475B1 (pt) Composições farmacêuticas na forma de lipossomas compreendendo ciclosporina a, seu método de preparo e usos
JP2019520361A (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
JP2025038163A (ja) 肺線維症を処置するための方法及び組成物
ES2974809T3 (es) Administración de iloprost en aerosol
WO2018132371A2 (en) Methods and compositions for treating pulmonary hypertension
WO2025180172A1 (zh) 一种含sgc受体激动剂的吸入混悬液制剂及其用途
JP2012506881A (ja) 肺動脈高血圧症の処置のためのヘリウム−酸素ガス混合物の使用
ES2787179T3 (es) Formulaciones de vilanterol
JP2025514305A (ja) 肺疾患を処置するための方法および組成物
TW202517265A (zh) 供吸入用之醫藥調配物及其用途
US20240398820A1 (en) Methods for treatment of pulmonary hypertension
EP4373481A1 (en) Pulmonary biguanide formulations
JP2025506019A (ja) トレプロスチニルイロプロスト併用療法
KR20250169548A (ko) 분무 건조 트레프로스티닐 제형
HK40096956A (zh) 治疗肺纤维化的方法和组合物
JPH0149692B2 (https=)
MXPA05011141A (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]